vga039

VGA039 is a fully human, IgG4 monoclonal antibody developed as a universal hemostatic therapy for bleeding disorders, with its lead indication being von Willebrand disease (VWD). It is administered subcutaneously and features a novel mechanism of action by targeting Protein S—a key cofactor in the regulation of thrombin generation during both initiation and propagation phases of coagulation. By attenuating Protein S cofactor function for tissue factor pathway inhibitor α (TFPIα) and activated protein C (aPC), VGA039 augments and restores thrombin generation, addressing fundamental deficiencies in clot formation seen in VWD. Clinical data show that VGA039 achieves sustained therapeutic concentrations with convenient dosing intervals, offering significant reductions in annualized bleed rates for patients with high baseline bleeding rates. The drug has received FDA Fast Track designation and Orphan Drug designation for VWD[1][2][3][4][5][6][7][8].